Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Lifted to Hold by Zacks Research

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks reports.

Several other analysts have also issued reports on PTHS. Alliance Global Partners restated a “buy” rating on shares of Pelthos Therapeutics in a report on Monday, October 26th. Oppenheimer lowered their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Friday, August 14th. Finally, Lake Street Capital dropped their price target on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.83.

Pelthos Therapeutics Price Performance

PTHS stock opened at $9.30 on Wednesday. The business has a fifty day moving average of $20.07 and a two-hundred day moving average of $23.91. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. The stock has a market cap of $35.62 million, a price-to-earnings ratio of -0.43 and a beta of 3.41. Pelthos Therapeutics has a 52-week low of $9.02 and a 52-week high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The business had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. As a group, research analysts anticipate that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE increased its position in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,919 shares of the company’s stock after acquiring an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).